Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Jan;147 Suppl 1(Suppl 1):S232-40.
doi: 10.1038/sj.bjp.0706400.

The role of inflammation in CNS injury and disease

Sian-Marie Lucas  1 , Nancy J Rothwell, Rosemary M Gibson
Affiliations
Review

The role of inflammation in CNS injury and disease

Sian-Marie Lucas et al. Br J Pharmacol. 2006 Jan.

Abstract

For many years, the central nervous system (CNS) was considered to be 'immune privileged', neither susceptible to nor contributing to inflammation. It is now appreciated that the CNS does exhibit features of inflammation, and in response to injury, infection or disease, resident CNS cells generate inflammatory mediators, including proinflammatory cytokines, prostaglandins, free radicals and complement, which in turn induce chemokines and adhesion molecules, recruit immune cells, and activate glial cells. Much of the key evidence demonstrating that inflammation and inflammatory mediators contribute to acute, chronic and psychiatric CNS disorders is summarised in this review. However, inflammatory mediators may have dual roles, with detrimental acute effects but beneficial effects in long-term repair and recovery, leading to complications in their application as novel therapies. These may be avoided in acute diseases in which treatment administration might be relatively short-term. Targeting interleukin (IL)-1 is a promising novel therapy for stroke and traumatic brain injury, the naturally occurring antagonist (IL-1ra) being well tolerated by rheumatoid arthritis patients. Chronic disorders represent a greater therapeutic challenge, a problem highlighted in Alzheimer's disease (AD); significant data suggested that anti-inflammatory agents might reduce the probability of developing AD, or slow its progression, but prospective clinical trials of nonsteroidal anti-inflammatory drugs or cyclooxygenase inhibitors have been disappointing. The complex interplay between inflammatory mediators, ageing, genetic background, and environmental factors may ultimately regulate the outcome of acute CNS injury and progression of chronic neurodegeneration, and be critical for development of effective therapies for CNS diseases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Downstream actions of IL-1. Brain injury and inflammation activate cells (e.g. microglia) leading to generation of IL-1, which acts on the IL-1 receptor (type 1) to activate diverse downstream effects. IL-1ra can inhibit the actions of IL-1.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. AISEN P.S., SCHAFER K.A., GRUNDMAN M., PFEIFFER E., SANO M., DAVIS K.L., FARLOW M.R., JIN S., THOMAS R.G., THAL L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819–2826. - PubMed
    1. BALOSSO S., RAVIZZA T., PEREGO C., PESCHON J., CAMPBELL I.L., DE SIMONI M.G., VEZZANI A. Tumor necrosis factor-alpha inhibits seizures in mice via p75 receptors. Ann. Neurol. 2005;57:804–812. - PubMed
    1. BECKER K., KINDRICK D., RELTON J.K., HARLAN J.M., WINN R. Antibody to the alpha4 integrin decreases infarct size in transient focal cerebral ischemia in rats. Stroke. 2001;32:206–211. - PubMed
    1. CAMPBELL A. Inflammation, neurodegenerative diseases, and environmental exposures. Ann. N.Y. Acad. Sci. 2004;1035:117–132. - PubMed
    1. COUZIN J. Clinical trials. Nail-biting time for trials of COX-2 drugs. Science. 2004;306:1673–1675. - PubMed

Substances